Prothena Partners Present Data Supporting Next Generation Treatments for Parkinsons and Alzheimers Disease at AD/PD 2026
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced...